MTCR — Metacrine Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $25.48m
- -$13.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.69 | ||
| Price to Tang. Book | 0.69 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -72.32% | ||
| Return on Equity | -90.72% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.45 | 1.45 | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Metacrine, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The Company’s advanced program targets the farnesoid X receptor (FXR), which is central to modulating GI and liver diseases. The Company’s pipeline includes MET642 and hydroxysteroid dehydrogenase 17B13 (HSD17B13 or HSD). MET642 is used for the treatment of inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s disease. HSD17B13 is used for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). The Company has built a proprietary library of approximately 2,500 FXR compounds.
Directors
- Richard Heyman NEC (63)
- Preston Klassen PRE (52)
- Trisha Millican CFO (47)
- Hubert Chen OTH (52)
- Kristina Burow IND (47)
- Ronald Evans IND (71)
- Andrew Guggenhime IND (51)
- Jeffrey Jonker IND (48)
- John McHutchison IND (63)
- Amir Nashat IND (47)
- Julia Owens IND (48)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- September 17th, 2014
- Public Since
- October 14th, 2021
- No. of Shareholders
- 37
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 43,832,832
- Address
- 4225 Executive Square, Suite 600, SAN DIEGO, 92037
- Web
- https://www.metacrine.com
- Phone
- +1 8583697800
- Contact
- Steve Kunszabo
- Auditors
- Ernst & Young LLP
Upcoming Events for MTCR
Q1 2023 Metacrine Inc Earnings Release
Q2 2023 Metacrine Inc Earnings Release
Q3 2023 Metacrine Inc Earnings Release
Similar to MTCR
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Advantis
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Metacrine share price?
As of Today at 01:14 UTC, shares in Metacrine are trading at $0.58. This share price information is delayed by 15 minutes.
How has the Metacrine share price performed this year?
Shares in Metacrine last closed at $0.58 and the price had moved by +23.7% over the past 365 days. In terms of relative price strength the Metacrine share price has outperformed the S&P500 Index by +9.17% over the past year.
What are the analyst and broker recommendations for Metacrine?
The overall consensus recommendation for Metacrine is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Metacrine dividend yield?
Metacrine does not currently pay a dividend.
Does Metacrine pay a dividend?
Metacrine does not currently pay a dividend.
When does Metacrine next pay dividends?
Metacrine does not currently pay a dividend.
How do I buy Metacrine shares?
To buy shares in Metacrine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Metacrine?
As of the previous close price of $0.58, shares in Metacrine had a market capitalisation of $25.48m.
Where are Metacrine shares listed?
Here are the trading details for Metacrine:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MTCR
What kind of share is Metacrine?
Based on an overall assessment of its quality, value and momentum Metacrine is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Metacrine share price forecast for 2023?
The analyst consensus target price for shares in Metacrine is $0.50. That is 14% below the last closing price of $0.58.
Analysts covering Metacrine currently have a consensus Earnings Per Share (EPS) forecast of -$0.54 for the next financial year.
Find out moreWhat is the trend in the Metacrine share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Metacrine. Over the past six months, its share price has outperformed the S&P500 Index by +21.73%.
As of the last closing price of $0.58, shares in Metacrine were trading +17.93% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Metacrine PE Ratio?
The Metacrine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Metacrine?
Metacrine's management team is headed by:
- Richard Heyman - NEC
- Preston Klassen - PRE
- Trisha Millican - CFO
- Hubert Chen - OTH
- Kristina Burow - IND
- Ronald Evans - IND
- Andrew Guggenhime - IND
- Jeffrey Jonker - IND
- John McHutchison - IND
- Amir Nashat - IND
- Julia Owens - IND